POSB17 Ozanimod for the Treatment of Biologic-Experienced Patients with Moderate-to-Severe Ulcerative Colitis: Results from a Systematic Literature Review and Network Meta-Analyses
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.127
https://www.valueinhealthjournal.com/article/S1098-3015(21)01922-7/fulltext
Title :
POSB17 Ozanimod for the Treatment of Biologic-Experienced Patients with Moderate-to-Severe Ulcerative Colitis: Results from a Systematic Literature Review and Network Meta-Analyses
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)01922-7&doi=10.1016/j.jval.2021.11.127
First page :
Section Title :
Open access? :
No
Section Order :
10857